000307536 001__ 307536
000307536 005__ 20260220120942.0
000307536 0247_ $$2doi$$a10.1111/ejh.70112
000307536 0247_ $$2pmid$$apmid:41489018
000307536 0247_ $$2ISSN$$a0902-4441
000307536 0247_ $$2ISSN$$a0036-553X
000307536 0247_ $$2ISSN$$a1600-0609
000307536 037__ $$aDKFZ-2026-00041
000307536 041__ $$aEnglish
000307536 082__ $$a610
000307536 1001_ $$aWalther, Dinah$$b0
000307536 245__ $$aEfficacy and Safety of Donor Lymphocyte Infusion After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
000307536 260__ $$aOxford$$bWiley-Blackwell$$c2026
000307536 3367_ $$2DRIVER$$aarticle
000307536 3367_ $$2DataCite$$aOutput Types/Journal article
000307536 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767623496_2785348
000307536 3367_ $$2BibTeX$$aARTICLE
000307536 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307536 3367_ $$00$$2EndNote$$aJournal Article
000307536 500__ $$aepub
000307536 520__ $$aThis retrospective study evaluates the efficacy and safety of donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT) in children. We describe the long-term use of preemptive, prophylactic, and therapeutic DLI with a gradual dose increase in half-log increments. Under close monitoring, we increased the DLI dose only in patients that did not show signs of graft-versus-host disease (GVHD). In the preemptive cohort, 10 of 12 patients (83%) with minimal residual disease (MRD) positivity remained relapse-free. Among 11 patients with genetic diseases and mixed chimerism, nine (82%) responded to preemptive DLI. Six patients (100%) of the prophylactic cohort with a very high risk of relapse had a successful outcome without relapse or GVHD. Three of the five patients (60%) of the therapeutic cohort were successfully treated with DLI. We observed acute GVHD (grade I and II) in only two patients (6%). The results of our study indicate that the long-term use of DLI is a promising strategy and can effectively prevent relapse, graft rejection, and even cure relapse. The observed low rate of GVHD may be attributed to the gradual dose increase. Therefore, we consider DLI a safe and effective therapeutic option.
000307536 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000307536 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307536 650_7 $$2Other$$adonor chimerism
000307536 650_7 $$2Other$$adonor lymphocyte infusion
000307536 650_7 $$2Other$$agraft‐versus‐host disease
000307536 650_7 $$2Other$$agraft‐versus‐leukemia effect
000307536 650_7 $$2Other$$ahematopoietic stem cell transplantation
000307536 7001_ $$aErnst, Jana$$b1
000307536 7001_ $$aWollenhaupt, Carola$$b2
000307536 7001_ $$aWittig, Susan$$b3
000307536 7001_ $$aHärtel, Manuela$$b4
000307536 7001_ $$aBrodt, Grit$$b5
000307536 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b6$$udkfz
000307536 7001_ $$aGruhn, Bernd$$b7
000307536 773__ $$0PERI:(DE-600)2027114-1$$a10.1111/ejh.70112$$gp. ejh.70112$$pnn$$tEuropean journal of haematology$$vnn$$x0902-4441$$y2026
000307536 8564_ $$uhttps://inrepo02.dkfz.de/record/307536/files/European%20J%20of%20Haematology%20-%202026%20-%20Walther%20-%20Efficacy%20and%20Safety%20of%20Donor%20Lymphocyte%20Infusion%20After%20Allogeneic.pdf$$yOpenAccess
000307536 8564_ $$uhttps://inrepo02.dkfz.de/record/307536/files/European%20J%20of%20Haematology%20-%202026%20-%20Walther%20-%20Efficacy%20and%20Safety%20of%20Donor%20Lymphocyte%20Infusion%20After%20Allogeneic.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000307536 909CO $$ooai:inrepo02.dkfz.de:307536$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000307536 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000307536 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000307536 9141_ $$y2026
000307536 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J HAEMATOL : 2022$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-06$$wger
000307536 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000307536 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-06
000307536 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-06
000307536 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x0
000307536 980__ $$ajournal
000307536 980__ $$aVDB
000307536 980__ $$aUNRESTRICTED
000307536 980__ $$aI:(DE-He78)B310-20160331
000307536 9801_ $$aFullTexts